Cargo Therapeutics is a San Mateo, CA–based biotechnology company advancing next-generation CAR T-cell therapies for cancer. Launched in 2021 by Samsara BioCapital in collaboration with CAR T pioneers Crystal Mackall, MD, and Robbie Majzner, MD, and cancer advocate Nancy Goodman, the company is led by CEO Gina Chapman. Cargo leverages proprietary platform technologies to engineer and develop next-generation, best-in-class CARs that incorporate complex therapeutic cargo. Its platform aims to achieve durable responses that are curative for more cancer patients. The company intends to use proceeds to advance its autologous CD22 CAR T candidate, CRG-022, through a pivotal multicenter Phase 2 trial in patients with LBCL whose disease has relapsed or is refractory to CD19 CAR T therapy. It will also use funds to advance its proprietary platform technologies and discovery-stage programs to deliver better outcomes for patients with high unmet need.

Total raised

$200M

Funding rounds

1

Latest round

Series A

Latest activity

Mar 2023